View Financial HealthRepligen 배당 및 자사주 매입배당 기준 점검 0/6Repligen 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률0.1%자사주 매입 수익률총 주주 수익률0.1%미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 07An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million.An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026. A cash consideration of $4.4 million will be paid by the buyer. As part of consideration, $4.4 million is paid towards common equity of SA Polymem. For the period ending December 31, 2025, SA Polymem reported total revenue of $7 million. An undisclosed buyer completed the acquisition of SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026.공시 • Apr 22Repligen Corporation to Report Q1, 2026 Results on May 05, 2026Repligen Corporation announced that they will report Q1, 2026 results Pre-Market on May 05, 2026공시 • Apr 03Repligen Corporation, Annual General Meeting, May 14, 2026Repligen Corporation, Annual General Meeting, May 14, 2026.공시 • Feb 24Repligen Corporation Provides Earnings Guidance for the Full Year 2026Repligen Corporation provided earnings guidance for the full year 2026. For the year, the company expects total reported revenue of $810 million to $840 million, Gross Margin of 53.6% to 54.1%, Income from Operations of $122 million to $130 million, Operating Margin of 15.1% to 15.5%, net income of $109 million to $114 million and Earnings per share - Diluted of $1.93 per share to $2.01 per share.공시 • Feb 10Repligen Corporation to Report Q4, 2025 Results on Feb 24, 2026Repligen Corporation announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 24, 2026공시 • Jan 07Repligen Corporation Announces Executive Changes, Effective March 13, 2026On January 6, 2026, Repligen Corporation announced that the Board of Directors has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. Dr. Madaus will succeed Tony J. Hunt, who is currently serving as the Executive Chair of the Board, following his previously announced March 2026 retirement, which shall be on the Effective Date, at which time Mr. Hunt will retire as a member of the Board. Mr. Hunt will continue to serve as an advisor to Repligen through March 2027. Martin D. Madaus, D.V.M., Ph.D., has served as a director of Repligen since February 2023. Dr. Madaus has 36 years of industry experience, including five years as Chairman, President and CEO of Millipore Corporation, where he was integral to the company’s transformation into a life science leader, and its acquisition by Merck KGaA in 2010. Dr. Madaus serves on the boards of Azenta Inc. and Hologic Inc. He holds a D.V.M. from the University of Munich in Germany and a Ph.D. from the University of Veterinary Medicine of Hanover in Germany.공시 • Dec 17Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality WorkflowsRepligen Corporation announced the launch of three new high-performance chromatography resins: AVIPure®? HiPer™? AAV9 and AVIPure®? Hi Per™? AAV8 affinity resins, along with HiPer™? QA anion-exchange resin, expanding the company's growing proteins portfolio and reinforcing its commitment to innovation in next-generation bioprocessing. Built on the Tantti™? DuloCore™? base bead technology, the new convective HiPer resins deliver the differentiated performance required for new modalities, including viral vectors. These solutions are engineered to help gene therapy developers accelerate product development, improve molecule stability, and enhance process economics, ultimately enabling faster, more reliable paths to market. As momentum continues across new modalities, Repligen remains focused on providing customers with the cutting-edge tools they need. These new resins extend the company's leadership in process productivity and strengthen its portfolio ahead of broader chromatography resin launches anticipated in 2026.Buy Or Sell Opportunity • Nov 06Now 21% undervaluedOver the last 90 days, the stock has risen 22% to €123. The fair value is estimated to be €155, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.2% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 45% per annum over the same time period.Reported Earnings • Oct 29Third quarter 2025 earnings released: EPS: US$0.27 (vs US$0.012 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.27 (up from US$0.012 loss in 3Q 2024). Revenue: US$188.8m (up 22% from 3Q 2024). Net income: US$14.9m (up US$15.6m from 3Q 2024). Profit margin: 7.9% (up from net loss in 3Q 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.공시 • Oct 29Repligen Corporation Updates Financial Guidance for the Full Year 2025Repligen Corporation updated financial guidance for the full year 2025. For the year, the total reported revenue of $729 million to $737 million, Income from Operations of $50 million to $52 million, net income of $46.5 million to $48 million and Earnings per share - Diluted of $0.82 per share to $0.85 per share.공시 • Oct 15Repligen Corporation to Report Q3, 2025 Results on Oct 28, 2025Repligen Corporation announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Oct 28, 2025공시 • Jul 29Repligen Corporation Updates Financial Guidance for the Full Year 2025Repligen Corporation updated financial guidance for the full year 2025. For the year total reported revenue of $715 million to $735 million, Income from Operations of $51 million- $56 million, net income of $48 million - $51.5 million and Earnings per share - Diluted of $0.85 per share - $0.92 per share.공시 • Jul 17Repligen Corporation to Report Q2, 2025 Results on Jul 29, 2025Repligen Corporation announced that they will report Q2, 2025 results at 9:30 AM, US Eastern Standard Time on Jul 29, 2025지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 1RGEN 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 1RGEN 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Repligen 배당 수익률 vs 시장1RGEN의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (1RGEN)n/a시장 하위 25% (IT)1.7%시장 상위 25% (IT)4.6%업계 평균 (Life Sciences)0.8%분석가 예측 (1RGEN) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 1RGEN 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 1RGEN 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 1RGEN 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 1RGEN 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIT 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/20 09:37종가2026/05/20 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Repligen Corporation는 29명의 분석가가 다루고 있습니다. 이 중 21명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Luke SergottBarclaysRobert WassermanBenchmark CompanyHugo SolvetBNP Paribas26명의 분석가 더 보기
공시 • May 07An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million.An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026. A cash consideration of $4.4 million will be paid by the buyer. As part of consideration, $4.4 million is paid towards common equity of SA Polymem. For the period ending December 31, 2025, SA Polymem reported total revenue of $7 million. An undisclosed buyer completed the acquisition of SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026.
공시 • Apr 22Repligen Corporation to Report Q1, 2026 Results on May 05, 2026Repligen Corporation announced that they will report Q1, 2026 results Pre-Market on May 05, 2026
공시 • Apr 03Repligen Corporation, Annual General Meeting, May 14, 2026Repligen Corporation, Annual General Meeting, May 14, 2026.
공시 • Feb 24Repligen Corporation Provides Earnings Guidance for the Full Year 2026Repligen Corporation provided earnings guidance for the full year 2026. For the year, the company expects total reported revenue of $810 million to $840 million, Gross Margin of 53.6% to 54.1%, Income from Operations of $122 million to $130 million, Operating Margin of 15.1% to 15.5%, net income of $109 million to $114 million and Earnings per share - Diluted of $1.93 per share to $2.01 per share.
공시 • Feb 10Repligen Corporation to Report Q4, 2025 Results on Feb 24, 2026Repligen Corporation announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 24, 2026
공시 • Jan 07Repligen Corporation Announces Executive Changes, Effective March 13, 2026On January 6, 2026, Repligen Corporation announced that the Board of Directors has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. Dr. Madaus will succeed Tony J. Hunt, who is currently serving as the Executive Chair of the Board, following his previously announced March 2026 retirement, which shall be on the Effective Date, at which time Mr. Hunt will retire as a member of the Board. Mr. Hunt will continue to serve as an advisor to Repligen through March 2027. Martin D. Madaus, D.V.M., Ph.D., has served as a director of Repligen since February 2023. Dr. Madaus has 36 years of industry experience, including five years as Chairman, President and CEO of Millipore Corporation, where he was integral to the company’s transformation into a life science leader, and its acquisition by Merck KGaA in 2010. Dr. Madaus serves on the boards of Azenta Inc. and Hologic Inc. He holds a D.V.M. from the University of Munich in Germany and a Ph.D. from the University of Veterinary Medicine of Hanover in Germany.
공시 • Dec 17Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality WorkflowsRepligen Corporation announced the launch of three new high-performance chromatography resins: AVIPure®? HiPer™? AAV9 and AVIPure®? Hi Per™? AAV8 affinity resins, along with HiPer™? QA anion-exchange resin, expanding the company's growing proteins portfolio and reinforcing its commitment to innovation in next-generation bioprocessing. Built on the Tantti™? DuloCore™? base bead technology, the new convective HiPer resins deliver the differentiated performance required for new modalities, including viral vectors. These solutions are engineered to help gene therapy developers accelerate product development, improve molecule stability, and enhance process economics, ultimately enabling faster, more reliable paths to market. As momentum continues across new modalities, Repligen remains focused on providing customers with the cutting-edge tools they need. These new resins extend the company's leadership in process productivity and strengthen its portfolio ahead of broader chromatography resin launches anticipated in 2026.
Buy Or Sell Opportunity • Nov 06Now 21% undervaluedOver the last 90 days, the stock has risen 22% to €123. The fair value is estimated to be €155, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.2% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 45% per annum over the same time period.
Reported Earnings • Oct 29Third quarter 2025 earnings released: EPS: US$0.27 (vs US$0.012 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.27 (up from US$0.012 loss in 3Q 2024). Revenue: US$188.8m (up 22% from 3Q 2024). Net income: US$14.9m (up US$15.6m from 3Q 2024). Profit margin: 7.9% (up from net loss in 3Q 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.
공시 • Oct 29Repligen Corporation Updates Financial Guidance for the Full Year 2025Repligen Corporation updated financial guidance for the full year 2025. For the year, the total reported revenue of $729 million to $737 million, Income from Operations of $50 million to $52 million, net income of $46.5 million to $48 million and Earnings per share - Diluted of $0.82 per share to $0.85 per share.
공시 • Oct 15Repligen Corporation to Report Q3, 2025 Results on Oct 28, 2025Repligen Corporation announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Oct 28, 2025
공시 • Jul 29Repligen Corporation Updates Financial Guidance for the Full Year 2025Repligen Corporation updated financial guidance for the full year 2025. For the year total reported revenue of $715 million to $735 million, Income from Operations of $51 million- $56 million, net income of $48 million - $51.5 million and Earnings per share - Diluted of $0.85 per share - $0.92 per share.
공시 • Jul 17Repligen Corporation to Report Q2, 2025 Results on Jul 29, 2025Repligen Corporation announced that they will report Q2, 2025 results at 9:30 AM, US Eastern Standard Time on Jul 29, 2025